What are mandatory monitoring requirements for clozapine use?

• A. No laboratory monitoring required.
• B. Regular ANC monitoring due to agranulocytosis risk; often weekly for first 6 months, then biweekly to monthly; monitor for myocarditis and infection; enrollment in Clozapine Registry.
• C. Monitoring only after 2 years of use.
• D. Monitoring only for lipid levels.

Answer: (B)

The safety feature being tested is the need for structured blood monitoring because clozapine carries a significant risk of agranulocytosis, a dangerous drop in neutrophils that can leave someone highly susceptible to infection. To catch this early, regular ANC checks are required. In practice, this means frequent lab monitoring started early in treatment—typically weekly for the first six months—then space out to every two weeks, and later to monthly if counts stay stable. Clinicians also stay alert for myocarditis and other signs of infection, especially in the early weeks and months of therapy. Enrollment in the Clozapine Registry ensures that providers, pharmacies, and laboratories are connected so the monitoring schedule is followed and any dangerous declines are acted on promptly. Lipid monitoring isn’t the central mandatory requirement for clozapine, though metabolic health remains important; the primary mandated monitoring is the hematologic safety plan with registry oversight.